Hoth Therapeutics, Inc. (HOTH)
Stock Price:
$2.50 USD
-0.08 (-3.10%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
33.55M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-8.70M |
| Shares Out |
13.42M |
| EPS (ttm) |
-0.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$2.50 |
| Previous Close |
$2.58 |
| Change ($) |
-0.08 |
| Change (%) |
-3.10% |
| Day's Open |
2.50 |
| Day's Range |
2.46 - 2.53 |
| Day's Volume |
153,141 |
| 52-Week Range |
2.31 - 7.87 |
More Stats
| Market Cap |
33.55M |
| Enterprise Value |
28.51M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.42M |
| Float |
5.78M |
| EPS (basic) |
-0.89 |
| EPS (diluted) |
-0.87 |
| FCF / Share |
-0.56 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
309,700 |
| Short Ratio |
0.33 |
| Short % of Float |
3.07% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
7.34 |
| Revenue |
n/a |
| Operating Income |
-8.69M |
| Net Income |
-8.70M |
| Free Cash Flow |
-5.77M |
| Net Cash |
5.04M |
| Net Cash / Share |
0.38 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-100.68% |
| ROE |
-170.74% |
| ROIC |
-2,216.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.00*
(300.00% upside)
Low
10.0
Current: 2.50
High
10.0
Target: 10.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -7.71 | -2.50 |
| Net Income | -7.70 | -2.50 |
| Shares Outstanding | 9.16 | 5.03 |
| Earnings Per Share | -0.84 | -0.50 |
| Operating Cash Flow | -4.95 | -2.10 |
| Free Cash Flow | -4.95 | -2.10 |
| Cash & Equivalents | 2.69 | 0.28 |
| Net Cash / Debt | 2.69 | 0.28 |
| Assets | 2.84 | 0.50 |
| Liabilities | 0.44 | 0.35 |
| Book Value | 2.40 | 0.15 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Hoth Therapeutics, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Robbie Knie |
Stock Information
| Ticker Symbol |
HOTH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HOTH |
Description
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Zylö Therapeutics, Inc.; Chelexa BioSciences, Inc.; and the University of Cincinnati. Hoth Therapeutics, Inc. was founded in 2017 and is headquartered in New York, New York.